The US Patent Office Grants BIOMARK Additional Patent for its LIQUID BIOPSY Technology
THE US PATENT OFFICE GRANTS BIOMARK ADDITIONAL PATENT FOR ITS LIQUID BIOPSY TECHNOLOGY Vancouver, British Columbia – (September 20, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that the US […]
BIOMARK SELECTED BY the Medical Alley and Investissement Quebec TO JOIN the US Go-to-Market Accelerator
BIOMARK SELECTED BY THE MEDICAL ALLEY AND INVESTISSEMENT QUEBEC TO JOIN THE US GO-TO-MARKET ACCELERATOR Vancouver, British Columbia – (September 1, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies is pleased to announce today that its Quebec-based wholly-owned subsidiary BioMark Diagnostic […]
Biomark to Expand Treatment Response Trial to Advanced Lung Cancer Patient Receiving Immunotherapy
Vancouver, British Columbia – (June 29th, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a […]
Alberta Research to Spot Early Stage Lung Cancer
Earlier and faster cancer detection is underway in Alberta Mikenomics | April 6, 2021 Earlier and faster cancer detection is the goal of research underway here in Alberta.With funding from the Spark Grants, The Metabolomics Innovation Centre (TMIC) based at the University of Alberta is leading the new effort. With funding from the Spark Grants, The Metabolomics Innovation Centre (TMIC) based […]
A Simple Blood Test to Detect Lung Cancer
A new project funded by the Canadian Cancer Society (CCS) could transform how lung cancer is detected and help save lives. Dr. David Wishart March 18, 2021 A new project funded by the Canadian Cancer Society (CCS) could transform how lung cancer is detected and help save lives. Lung cancer is the most commonly diagnosed […]
U of Alberta Researchers Win $120K Grant to Develop Metabolite-Based Lung Cancer Test
Mar 16, 2021 | staff reporter NEW YORK — BioMark Diagnostics said on Tuesday that its collaborators at the University of Alberta’s Metabolomics Innovation Centre have been awarded a C$150,000 (US$120,327) grant to evaluate the company’s metabolite biomarker panel for early lung cancer detection. The funding is being provided through a cancer technology grant program sponsored by […]
Yearly Lung Cancer Scans Are Advised for People 50 and Over With Shorter Smoking Histories
New advice from an influential panel will make more women and African-Americans eligible for CT scans, but some who need them most may not be able to afford them. By Denise Grady March 9, 2021Updated 3:33 p.m. ET New guidelines from medical experts will nearly double the number of people in the United States who are advised […]
BIOMARK DIAGNOSTICS TARGETS RESPONSE TO TREATMENT APPLICATION WITH ITS LIQUID BIOPSY PLATFORM
Vancouver, British Columbia – (February 8, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Use of Amantadine in the Evaluation of Response to Chemotherapy in Lung Cancer – a Pilot Study” has been published in the peer-reviewed journal Future Science OA. Rashid A. Bux, […]
World Cancer Day: A leading international awareness day
World Cancer Day every 4 February is the global uniting initiative led by the Union for International Cancer Control (UICC). By raising worldwide awareness, improving education and catalysing personal, collective and government action, we’re working together to reimagine a world where millions of preventable cancer deaths are saved and access to life-saving cancer treatment and care is equal for all – no matter who […]
BIOMARK’S LIQUID BIOPSY SCIENTIFIC PAPER TO BE FEATURED AS COVER ON CANCERS UPCOMING ISSUE
Vancouver, British Columbia – (August 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study” will be on cover of Cancers. Rashid Ahmed, President and CEO, says, “This latest paper […]
